X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs WOCKHARDT LTD. - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES WOCKHARDT LTD. DIVIS LABORATORIES/
WOCKHARDT LTD.
 
P/E (TTM) x 18.5 17.1 107.7% View Chart
P/BV x 4.0 1.7 228.5% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 DIVIS LABORATORIES   WOCKHARDT LTD.
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
WOCKHARDT LTD.
Mar-16
DIVIS LABORATORIES/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs2,4842,000 124.2%   
Low Rs918706 130.1%   
Sales per share (Unadj.) Rs142.3403.7 35.2%  
Earnings per share (Unadj.) Rs41.929.5 142.1%  
Cash flow per share (Unadj.) Rs46.342.4 109.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs161.5323.4 49.9%  
Shares outstanding (eoy) m265.47110.51 240.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.03.4 356.8%   
Avg P/E ratio x40.645.9 88.5%  
P/CF ratio (eoy) x36.731.9 115.0%  
Price / Book Value ratio x10.54.2 251.7%  
Dividend payout %23.90-   
Avg Mkt Cap Rs m451,525149,509 302.0%   
No. of employees `0003.77.4 50.3%   
Total wages/salary Rs m3,6499,443 38.6%   
Avg. sales/employee Rs Th10,184.46,048.6 168.4%   
Avg. wages/employee Rs Th984.11,280.2 76.9%   
Avg. net profit/employee Rs Th2,998.5441.5 679.1%   
INCOME DATA
Net Sales Rs m37,76444,614 84.6%  
Other income Rs m848970 87.5%   
Total revenues Rs m38,61245,584 84.7%   
Gross profit Rs m14,1385,038 280.6%  
Depreciation Rs m1,1821,426 82.9%   
Interest Rs m231,012 2.3%   
Profit before tax Rs m13,7813,570 386.0%   
Minority Interest Rs m0-65 0.0%   
Prior Period Items Rs m06 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,662255 1,044.9%   
Profit after tax Rs m11,1193,257 341.4%  
Gross profit margin %37.411.3 331.5%  
Effective tax rate %19.37.1 270.7%   
Net profit margin %29.47.3 403.4%  
BALANCE SHEET DATA
Current assets Rs m30,94739,906 77.5%   
Current liabilities Rs m5,19518,423 28.2%   
Net working cap to sales %68.248.2 141.6%  
Current ratio x6.02.2 275.0%  
Inventory Days Days11790 129.5%  
Debtors Days Days8598 86.7%  
Net fixed assets Rs m17,02735,832 47.5%   
Share capital Rs m531553 96.1%   
"Free" reserves Rs m42,34130,370 139.4%   
Net worth Rs m42,87735,739 120.0%   
Long term debt Rs m516,542 0.0%   
Total assets Rs m49,68479,522 62.5%  
Interest coverage x595.04.5 13,142.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.80.6 135.5%   
Return on assets %22.45.4 417.8%  
Return on equity %25.99.1 284.6%  
Return on capital %32.28.7 372.0%  
Exports to sales %85.311.6 734.8%   
Imports to sales %22.94.5 513.7%   
Exports (fob) Rs m32,1985,177 622.0%   
Imports (cif) Rs m8,6541,990 434.9%   
Fx inflow Rs m32,2707,589 425.2%   
Fx outflow Rs m8,7752,878 304.8%   
Net fx Rs m23,4964,711 498.8%   
CASH FLOW
From Operations Rs m10,379716 1,449.4%  
From Investments Rs m-4,135-8,182 50.5%  
From Financial Activity Rs m-6,2412,543 -245.5%  
Net Cashflow Rs m3-4,923 -0.1%  

Share Holding

Indian Promoters % 52.0 74.5 69.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 2.3 513.0%  
FIIs % 19.0 7.7 246.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.2 15.4 111.7%  
Shareholders   31,796 67,757 46.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 17, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - DR. DATSONS LABS COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS